Commitments and Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2017 USD ($) Employee	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Commencement date of lease				2015-09
Acquisition of leasehold improvements				$ 445
Lease amendment commencement date			Jul. 01, 2016
Lease term			90 months
Lease extension term			5 years
Lease description			The lease term is 90 months and Inotek has the right to extend the term for one period of five years.
Operating leases, rent expenses		$ 337	$ 275
Fees owe to advisor upon change in control		$ 528	311
Merger agreement consummation Date		Jan. 04, 2018
Research and development expense		$ 14,193	31,985
Stock options expected to vest during period		$ 4,036	2,909
Transition Agreement [Member]
Operating Leased Assets [Line Items]
Description of Transition Agreement		Pursuant to the terms of the Transition Agreement, Dr. McVicar remained an employee of the Company as a Senior Advisor for a six-month period ending April 4, 2017 (the “Transition Period”) and for twelve months thereafter will receive his salary and medical benefits at the same rate in effect as of the date of the Transition Agreement.
Former Chief Scientific Officer [Member] | Transition Agreement [Member]
Operating Leased Assets [Line Items]
Research and development expense			862
Payments to former employee on termination		$ 591
Bonus paid to former employee on his termination		102
Accrued severance		$ 106
Former Chief Scientific Officer [Member] | Transition Agreement [Member] | Stock Options [Member]
Operating Leased Assets [Line Items]
Stock options expected to vest during period			$ 215
Whitehead v. Inotek Pharmaceuticals Corporation [Member] | Pending Litigation [Member]
Operating Leased Assets [Line Items]
Lawsuit filing date		January 6, 2017
Amended complaint filing date		July 10, 2017
Second amended complaint filing date		September 5, 2017
Name of plaintiff		purported stockholder of Inotek
Lawsuit action domicile		U.S. District Court for the District of Massachusetts
Name of defendant		David Southwell, and Rudolf Baumgartner
Lawsuit allegation, description		The second amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against the Company, David Southwell, and Rudolf Baumgartner based on allegedly false and misleading statements and omissions regarding Inotek’s phase 2 and phase 3 clinical trials of trabodenoson.
Lawsuit management action, description		The lawsuit seeks, among other things, unspecified compensatory damages for purchasers of Inotek’s common stock between July 23, 2015 and July 10, 2017, as well as interest and attorneys’ fees and costs. The defendants filed a motion to dismiss the second amended complaint on October 6, 2017, the plaintiffs opposed the motion on December 5, 2017, and the defendants filed a reply on January 16, 2018. Inotek continues to vigorously defend itself against this claim.
Plaintiffs opposed motion date		Dec. 05, 2017
Defendants filed a reply date		Jan. 16, 2018
Change-in-Control Benefits [Member]
Operating Leased Assets [Line Items]
Employment termination benefits, description		In September 2017, Inotek modified the employment agreements with certain of its remaining employees such that in the event of termination in connection with a change in control (“CIC”), Inotek will provide these employees severance payments at each employee’s current monthly salary rate, and continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost) for up to six months primarily depending on duration of each individual employee’s service. Inotek also modified the employment agreements with certain of its named executive officers. In the event of a qualifying termination in connection with a CIC, for each of Inotek’s Chief Medical Officer and Vice President, Finance, Inotek will pay (i) twelve and six months’ severance, respectively, at each person’s current monthly salary rate, and (ii) continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for twelve and six months, respectively. In the event of a qualifying termination in connection with a CIC, in addition to the severance benefits previously provided to Inotek’s Chief Executive Officer (consisting of a lump-sum payment equal to 18 months’ base salary), Inotek agreed to provide continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for eighteen months.
Number of remaining employees eligible for retention bonus | Employee	7
Retention bonus payable in aggregate	$ 642
Change-in-Control Benefits [Member] | Perella Weinberg Partners, LP [Member] | Merger of Rome Merger Sub with and into Rocket Pharmaceuticals, Ltd [Member]
Operating Leased Assets [Line Items]
Fees owe to advisor upon change in control	$ 2,000